2 billion for Hep B? Think ur a zero out there mate. Then...

First 2 Last

Share
Profile

Follow
grunter7956

2,912 Posts.

405

05/06/15

13:24

Post #: 15420369
Share

Originally posted by hindmost ↑

There's a lot of comment here on HC (including mine) about how BLT is worth much more than its current market cap. So, what is a fair value for BLT today?

In round figures, a 1-shot cure for HIV/Aids would be worth north of $2bn, of Hep C probably well north of $7bn (10x the victims of HIV), of Hep B say another $2bn. Ignoring other targets say $11bn in total. Odds against a bio succeeding from PhI/II are generally I think put at around 10:1. So we're down to $1.1bn. But to get there, more cash is needed. Let's assume mgt aren't stupid and that they use a mix of debt and equity and that they wait for efficacy before an IPO. That should see no more than the equivalent of say 50% dilution. So now we're down to $550m. But it's going to take say 2 years before any real earnings, so discounting at say 15%pa, we're down to $415m. Now we need to allow a bit of leeway in the market, say 30%, giving NPV $290m, or share price today 2.47.

Play with those figures how you like, but it seems that BLT right now is a gift at anything much below $2.

Any different ideas, anyone?

Expand

2 billion for Hep B? Think ur a zero out there mate. Then there's macular degeneration - another few billion. Any virus known to mankind is there for the taking somewhere down the line.
Agree it should be around the $2 mark today with an enormous upside.

BLT Price at posting: 77.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: BHP shares rise with iron ore – but so does CBA

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

TMG

Investors cautious as Trigg Minerals issues unusual trading halt

Thursday's HotCopper trends: Mystery Trigg halt, Neurizon FDA feedback | July 10

AII

Inside the depths of Panasqueira: A legacy carved in rock

First 2 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

2 billion for Hep B? Think ur a zero out there mate. Then...

Top Stories

ASX Market Close: BHP shares rise with iron ore – but so does CBA

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Investors cautious as Trigg Minerals issues unusual trading halt

Thursday's HotCopper trends: Mystery Trigg halt, Neurizon FDA feedback | July 10

Inside the depths of Panasqueira: A legacy carved in rock

Featured News